Aaron B Mendelsohn

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Systemic Lupus Erythematosus

Health Insurance

Diffuse Large B Cell Lymphoma

Top Venues

Journal of medical economics

Drugs - real world outcomes

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Catherine M Lockhart, Cara L McDermott, Aaron B Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A DeFor, Pamala A Pawloski
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm. Journal of medical economics 26 (1) (2023)
Catherine M Lockhart, Cara L McDermott, Aaron B Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A DeFor, Pamala A Pawloski
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm. Journal of medical economics (2023)
Young Hee Nam, Sarah J Willis, Aaron B Mendelsohn, Susan Forrow, Bradford D Gessner, James H Stark, Jeffrey S Brown, Sarah Pugh
Healthcare claims-based Lyme disease case-finding algorithms in the United States: A systematic literature review. PloS one 17 (10) (2022)
Aaron B Mendelsohn, James Marshall, Cara L McDermott, Pamala A Pawloski, Jeffrey S Brown, Catherine M Lockhart
Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product. Drugs - real world outcomes 8 (2) (2021)
Aaron B Mendelsohn, Young Hee Nam, James Marshall, Cara L McDermott, Bharati Kochar Ms, Michael D Kappelman, Jeffrey S Brown, Catherine M Lockhart
Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population. Pharmacology research & perspectives 9 (1) (2021)